Mindpeak AI Featured in first-of-its Kind Study on Neuroendocrine Neoplasms

March 13, 2025

Ki-67 + SSRT2A NEN Pilot Study featuring Mindpeak GmbH

We’re excited to share that our AI-powered pathology algorithms were an integral part in a pioneering study on AI-assisted SSRT2A and Ki-67 readout in neuroendocrine neoplasms (NEN). T

he work was recently presented at the 22nd ENETS Conference in Krakow, Poland by PD Dr. med. Daniel Kaemmerer.

The study demonstrated that Mindpeak’s AI delivers clinical-grade performance for IHC scoring in NEN:

✅ 92% agreement with manual evaluation for SSTR2A (pos. vs. neg.)

✅ High interobserver reliability for Ki-67 (Krippendorff's α = 0.83)

✅ System usability score (SUS) of 75 (Grade B)

This proof-of-concept marks another step forward on our mission to bring AI-assisted diagnostics into broad routine pathology, supporting pathologists for more efficient, accurate and reproducible diagnoses.

“AI is not replacing pathologists—it’s empowering them!” summarizes Dr. Kämmerer.

"This study confirmed that AI-powered digital pathology is no longer a vision for the future—it’s a reality today. With high accuracy and usability, Mindpeak’s AI software can support pathologists in making faster, more reliable diagnoses."

A huge thank you to PD Dr. med. Daniel Kaemmerer and the research team for pioneering AI use in neuroendocrine neoplasms.

In the News

Related reading

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.
In the News
8 min read

Mindpeak in Oncology Times

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

As Patrick notes, the conversation must move from if to how. The science and technology already exist; now it’s about ensuring every patient, everywhere, can access and benefit from them.

At Mindpeak, we believe AI-powered pathology can help close that gap – supporting faster, more consistent insights that make precision medicine truly accessible.

In the News
8 min read

AI-Enabled Pathology: De-risking Oncology Drug Development

We are delighted to share that Aurélie Fugon, VP Predictive AI Solutions at Mindpeak, is featured in Life Science Daily News.

In her article, Aurélie outlines how AI-supported biomarker-driven strategies can reduce variability in pathology, improve the consistency of patient selection and help de-risk late-stage trials.

All key enablers of more reliable, data-rich clinical decision-making. With Aurélie’s leadership, we’re strengthening collaborations with pharma, biotech and clinical partners to help bring reproducible, scalable biomarker assessment into real-world research settings, shaping the future of predictive AI in precision oncology.

Read the full article here: https://lifesciencedaily.news/ai-enabled-pathology-de-risking-oncology-drug-development/

In the News
8 min read

United by Unique: Advancing Personalised Cancer Care on World Cancer Day

Every person with cancer is unique. So is every diagnosis - and every pathology sample that informs it.

This year’s World Cancer Day theme continues the focus on United by Unique, highlighting the importance of early detection, equitable access, and truly personalised care. It is a powerful reminder that behind every case is an individual with distinct biology, circumstances, and needs.

At Mindpeak, we believe precision medicine should be a right, not a privilege. Scientific and technological advances have transformed what is possible in cancer diagnostics. The challenge now is ensuring these innovations reach patients in ways that reflect their individuality.

Advanced AI models in digital pathology can help bridge this gap. By accelerating insights from complex tissue data and supporting clinicians with consistent, high-quality analysis, AI contributes to faster, more precise and more personalised decision-making.

On World Cancer Day, we stand with the global community in raising awareness and championing approaches that put people first. When we see the person before the disease, we move closer to a future where every individual’s uniqueness is recognized - and reflected - in their care.

Ready to advance your diagnostics

Connect with our team to explore how precision pathology works in your setting